CITRATE ANTICOAGULATION FOR HAEMOFILTRATION

Similar documents
Replacement post-filter (ml/hr) Blood flow (ml/min) Dialysate (ml/hr) Weight (kg)

Continuous Renal Replacement Therapy. Jai Radhakrishnan, MD, MS

INTRAVENOUS FLUIDS. Acknowledgement. Background. Starship Children s Health Clinical Guideline

ELECTROLYTE SOLUTIONS (Continued)

Acid-Base Balance and the Anion Gap

Type Description Advantage Disadvantage. Available in large diameter Ease of insertion

Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV

0.9% Sodium Chloride injection may be used in most cases.


ACID-BASE DISORDER. Presenter: NURUL ATIQAH AWANG LAH Preceptor: PN. KHAIRUL BARIAH JOHAN

3 Which fluid and why?

Mind the Gap: Navigating the Underground World of DKA. Objectives. Back That Train Up! 9/26/2014

ACID- BASE and ELECTROLYTE BALANCE. MGHS School of EMT-Paramedic Program 2011

PREPARATIONS: Adrenaline 1mg in 1ml (1:1000) Adrenaline 100micrograms in 1ml (1:10,000)

Lung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)

The early symptoms of acute salicylism are the triad of gastrointestinal distress, tinnitus or altered hearing, and hyperventilation.

Lothian Diabetes Handbook MANAGEMENT OF DIABETIC KETOACIDOSIS

Anticoagulant therapy

GUIDANCE FOR INTRAVENOUS FLUID AND ELECTROLYTE PRESCRIPTION IN ADULTS

Provision of Intravenous EDTA Chelation as a Complementary and Alternative Medicine

Metabolic alkalosis. ICU Fellowship Training Radboudumc

Select the one that is the best answer:

Hyperosmolar Non-Ketotic Diabetic State (HONK)

Magnesium (serum, plasma)

Dr. Johnson PA Renal Winter 2010

Is there a role for sodium bicarbonate in treating lactic acidosis from shock? John H. Boyd and Keith R. Walley

The Hemodialysis Machine Case Study

Treatment Recommendations for CKD in Cats (2015)

TYPE 2 DIABETES MELLITIS (INSULIN AND/OR METFORMIN) CARE OF WOMEN IN BIRTHING SUITE

The Golden Rule of Specimen Collection: The Patient Test Result is Only as Good as the Sample We Get

Transfusion Medicine

Diabetic Ketoacidosis

PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)

3% Sodium Chloride Injection, USP 5% Sodium Chloride Injection, USP

6 Easy Steps to ABG Analysis

Paediatric fluids 13/06/05

Acid-Base Disorders. Jai Radhakrishnan, MD, MS. Objectives. Diagnostic Considerations. Step 1: Primary Disorder. Formulae. Step 2: Compensation

Electronic copy to all appropriate staff Intranet Notification in Staff Focus Related Trust Policies (to be read in conjunction with)

Cyclophosphamide/Rabbit Anti-Thymocyte Globulin for Allograft

Potassium Replacement

Acid/Base Homeostasis (Part 3)

LECTURE 1 RENAL FUNCTION

ONCE ONLY GLUCAGON and Fast Acting Glucose gel (PGD) For nurse administration under Patient Group Direction (Trust wide PGD in place)

Eileen Whitehead 2010 East Lancashire HC NHS Trust

Anticoagulation guidelines for chronic and acute hemodialysis patients

Laboratory Monitoring of Adult Hospital Patients Receiving Parenteral Nutrition

Diabetic Ketoacidosis: When Sugar Isn t Sweet!!!

Acid-Base Balance and Renal Acid Excretion

This is a preprint file scheduled to be published in Artificial Organs later this year (2012). It is

Portex Arterial Blood Sampling Kits

University of Gezira. Faculty of Medicine. Department of Paediatrics and Child Health. Integrated Management of Diabetes in Children (IMDC) Project

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

Recommendations: Other Supportive Therapy of Severe Sepsis*

CRRT with Prismaflex LEADS TO More Flexibility, Ease of Use and Safety

Balancing Chemical Equations

Central Line Blood Draw

IV solutions may be given either as a bolus dose or infused slowly through a vein into the plasma at a constant or zero-order rate.

Suffolk County Community College School of Nursing NUR 133 ADULT NURSING I

Dengue haemorrhagic fever CHAPTER 3. Treatment

ACID-BASE BALANCE AND ACID-BASE DISORDERS. I. Concept of Balance A. Determination of Acid-Base status 1. Specimens used - what they represent

CRRT: I and O. I and O Sheet

EXPERIMENT # 3 ELECTROLYTES AND NON-ELECTROLYTES

FLUID & ELECTROLYTE THERAPY Lyon Lee DVM PhD DACVA

GESTATIONAL DIABETES (DIET/INSULIN/METFORMIN) CARE OF WOMEN IN BIRTHING SUITE

Acid-Base Disorders. Jai Radhakrishnan, MD, MS

Dabigatran (Pradaxa) Guidelines

Dr Gordon Royle Haematologist, Middlemore Hospital

The PRISMAFLEX System. Making possible personal.

THE PRISMAFLEX SYSTEM

2011 EBM-hyperglycemia

Hydration Protocol for Cisplatin Chemotherapy

Ultrafiltration Devices

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

Milliequivalents, Millimoles,, and Milliosmoles

Subsequent transfusions should be done with RBCs that are compatible with that of the mother and infant.

0.9% Sodium Chloride Injection, USP In VIAFLEX Plastic Container

Dorset Cardiac Centre

Reversal of Anticoagulants at UCDMC

Calcium (serum, plasma, blood)

PRISMAFLEX CRRT SYSTEM

Dr Gordon Royle Haematologist, Middlemore Hospital

Week 30. Water Balance and Minerals

Case Study. Objectives

Tutorial 4 SOLUTION STOICHIOMETRY. Solution stoichiometry calculations involve chemical reactions taking place in solution.

Phosphate (serum, plasma, urine)

Syre-base regulering og bikarbonat

Crash Cart Drugs Drugs used in CPR. Dr. Layla Borham Professor of Clinical Pharmacology Umm Al Qura University

Drug Excretion. Renal Drug Clearance. Drug Clearance and Half-Life. Glomerular Filtration II. Glomerular Filtration I. Drug Excretion and Clearance

Success criteria You should be able to write the correct formula for any ionic compound

Renal Acid/Base. Acid Base Homeostasis... 2 H+ Balance... 2

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

ION EXCHANGE FOR DUMMIES. An introduction

Acid/Base Homeostasis (Part 4)

Correspondence

BSPED Recommended Guideline for the Management of Children and Young People under the age of 18 years with Diabetic Ketoacidosis 2015

Investigation and treatment of liver disease with acute onset Local hospital protocol

Jeopardy Topics: THE CLOT STOPS HERE (anticoagulants) SUGAR, SUGAR, HOW D YOU GET SO HIGH (insulins)

Guidelines on the Management and Investigation of Acute Renal Failure Renal Unit Royal Hospital for Sick Children Yorkhill Division

Return to Lab Menu. Stoichiometry Exploring the Reaction between Baking Soda and Vinegar

Transcription:

CITRATE ANTICOAGULATION FOR HAEMOFILTRATION Background Patients on continuous modes of renal replacement therapy require anticoagulation to prevent clotting of blood in the extracorporeal circuit. Adequate anticoagulation prolongs circuit life but how long the membrane remains effective is debatable. Changing the filter every 48 hours is about right. Citrate anticoagulation prolongs circuit life and causes less bleeding when compared with heparin. Citrate Anticoagulation Citrate acts by chelating calcium ions that are essential in the clotting cascade. It also chelates other divalent cations including magnesium and aluminium. A plasma citrate concentration of about 5-6 mmol/l is required in order to reduce ionised calcium concentration to less than 0.6 mmol/l, which is required for anticoagulation. Adding approximately 2-3 mmol of citrate per litre of blood flowing through the filter usually achieves this. Most of the added citrate returns to the patient and is metabolised rapidly by the liver, though there is a continuously slightly elevated systemic plasma citrate level which chelates some calcium in the systemic circulation. This can lead to a low systemic ionised calcium level even with normal total calcium. Also some chelated calcium is filtered, and as the substitution fluid contains no calcium there is a net loss of approx 2-3 mmol/kg/day in the filtrate. In order to avoid systemic ionised hypocalcaemia, a separate infusion of calcium is required at a rate of approx. 2mmol/kg/day for a blood flow of 5ml/kg/min, and this is adjusted to maintain systemic plasma ionised calcium level of approx. 0.9-1.2 mmol/l. To achieve optimal anticoagulation within the circuit using a citrate based substitution solution there must be a balance between circuit blood flow and substitution fluid flow rate. This ratio between citrate dose and circuit blood flow remains reasonably fixed allowing the prediction of what citrate dose (substitution flow rate) is needed for a particular blood flow rate. A separate magnesium infusion may be necessary. Citrate is metabolised to bicarbonate (3 molecules per molecule of citrate), mostly in the liver. A metabolic alkalosis therefore develops in protocols which add citrate separately (even when some of the citrate is as citric acid, eg acid-citrate dextrose), and hypernatraemia if the citrate is added as trisodium citrate. This is minimised if sodium citrate is an integral component of the substitution fluid, the citrate acting as the base instead of bicarbonate. This only happens if the liver is able to metabolise the citrate load. Author: David Buckley Page 1 of 8 Issued:

PROTOCOL NB: The circuit should be primed with 0.9% Saline Relative Contraindications Citrate anticoagulation may NOT be an option for: Patients with severe hepatic dysfunction. Patients with Citrate lock, where citrate has accumulated during citrate anticoagulation. These patients will need heparinisation as per the standard policy. Patients with coagulopathy (ACT >200 sec, or APTT > twice normal) MAY have neither heparin nor citrate, and bicarbonate-based substitution fluid is used. Substitution Fluid Made commercially in 5 Litre bags by Baxter/Edwards Life Sciences. Be careful to distinguish between the 5 Litre bags containing citrate and those that are lactate free. Composition cannot be adjusted, except for the addition of Potassium Chloride or Phosphate, or Sodium Phosphate if needed, as per CVVH protocol. Potassium should be added to the substitution fluid to maintain the serum potassium @ 4mmol/l. This can be achieved by adding 15mmol of either KCl or KH 2 PO 4 to each 5 litre bag. The composition is: Sodium 140 mmol/l Potassium 1 mmol/l Chloride 99 mmol/l Citrate 14 mmol/l (42 meq/l) Trisodium citrate dihydrate. ALL the substitution fluid must be added Pre-Filter, never Post-Filter. Author: David Buckley Page 2 of 8 Issued:

PERFORMING CVVH Step 1 Flow rates 1. Maximum blood flow rate achievable will vary with catheter size. Ranges for the different catheters are: 6.5F 20-60mls/min. Use for up to 10kg 8.5F 50-100mls/min. Use for 11-29kg 11F 90-200mls/min. Use for 30kg+ Aim for a blood flow rate of 4ml/kg/min with a minimum of 20ml/min. Once blood flow rate established commence substitution flow rate @ 35ml/kg/hr after 15 minutes and begin filtrate removal @ desired rate. For different flow rates see Table 1 below. Table 1. Initial blood flow rates and substitution fluid flow rates INITIAL 35 ml/kg/hr 48 ml/kg/hr 56ml/kg/hr Substitution flow rate Blood flow rate 4 ml/kg/min 5 ml/kg/min 6 ml/kg/hr Approximate clearances of urea/creatinine 40 ml/kg/hr 50 ml/kg/hr 60.ml/kg/hr INITIAL 10% CaGluconate infusion rate 2. Filtrate flow rate 0.30 ml/kg/hr 0.36 ml/kg/hr 0.42 ml/kg/hr Start at 35ml/kg/hr, i.e. the same rate as the substitution fluid. Once patient stable, increase filtrate rate to achieve desired fluid balance. NB: Do not have less than 4 ml/kg/min blood flow and 35 ml/kg/hr substitution flow unless the blood flow is limited by access problems and can not be increased to this rate.in this case you need to decrease the substitution fluid rate to match the blood flow rate. There is evidence from adult studies that show that 35ml/kg/hr filtration rate has a survival advantage over lower rates. 3. Fluid Removal Net fluid balance for the patient is the sum of ALL ingoing fluid minus ALL outgoing fluid. Author: David Buckley Page 3 of 8 Issued:

Step 2 Calcium Infusion Plasma ionised calcium must be normalised prior to starting this treatment (>1.0 mmol/l). Calcium Gluconate 10% contains 0.22mmol Calcium/ml. Give a bolus if necessary (0.5 ml/kg 10% Calcium Gluconate over 30 min). A separate infusion of 10% calcium gluconate (undiluted) is set up into a separate central venous catheter. Initial infusion rate is at 0.36ml/kg/hr of 10% Calcium Gluconate for each 5 ml/kg/min of blood flow. Step 3 Magnesium Replacement a) Plasma magnesium must be normalised prior to starting this treatment (>0.7 mmol/l). Give a bolus if necessary (0.2 mmol/kg MgSO 4 IV over 60 min). b) 50% magnesium sulphate (undiluted) 0.2 mmol/kg (0.1 ml/kg) should be given every 12 hours while citrate is running, into a separate central venous catheter (if a spare lumen is available) or into the venous return limb of the circuit Do not mix it with calcium. c) The plasma magnesium should be measured 12 hrly. If it falls to 0.7 mmol/l give an extra 0.2 mmol/kg of Magnesium Sulphate and decrease the interval between regular doses to 8 hours while citrate is running. Step 4 Monitoring and Adjusting the Circuit (Post-Filter) Ionised Calcium a) Plasma ionised calcium in the circuit must be measured to ensure effective anticoagulation. b) Take blood samples from the blue port in the return limb of the circuit close to the blue end of the filter (post-filter). Use a non-heparinised syringe. Analyse it in the blood gas machine to determine the base-line ionised calcium level. Take a blood sample after 15 min of treatment, then after one hour, and 12-hourly thereafter, to analyse the ionised calcium level. REPEAT this sampling regimen whenever changes are made to the calcium infusion rate or the substitution fluid rate. c) The circuit ionised calcium level should be between 0.25 and 0.50 mmol/l. Adjust the substitution flow rate (and thereby the citrate flow rate), Table 2 without adjusting the blood flow rate if the ionised calcium level is outside this range. NB: This will change the overall fluid balance and you will need to remove more or less fluid per hour if you want the net fluid balance to remain unchanged. Do not go below 35ml/kg/hr of substitution fluid unless limited by blood flow rate. Sequential adjustments may be needed before stabilisation of the circuit ionised calcium. Author: David Buckley Page 4 of 8 Issued:

Table 2. Adjusting the citrate infusion rate (i.e. the substitution flow rate) Circuit ionised calcium Action (Ca i ) <0.25 mmol/l Decrease substitution rate by 10% 0.25-0.50 mmol/l (Optimum) No adjustment >0.5 mmol/l Increase substitution rate by 10% Do not adjust blood flow rate Step 5 Monitoring and Adjusting the Systemic (Patient) Ionised Calcium d) Arterial or venous blood gases from a separate arterial or venous line should be performed hourly initially, to measure systemic ionised calcium. Ionised calcium must be kept in the range 0.9-1.2 mmol/l. Adjust the separate calcium gluconate infusion according to Table 3. Sequential adjustments may be needed. Table 3. Adjusting the Calcium Gluconate Infusion Rate Systemic ionised calcium (Ca i ) Action >1.2 Decrease Ca Gluconate rate by 10% 1.0-1.2 mmol/l (optimum) No adjustment 0.8-0.99 Increase Ca Gluconate rate by 10%. Bolus Ca Gluconate if CVS unstable (see below) <0.8 Give 0.3ml/kg over 10 min and increase Ca Gluconate rate by 10% Record both the circuit ionised calcium and the patient s ionised calcium in the respective lines on the CVVH sheet. Sample patient ionised calcium hourly until stable. After 4 hours the hourly sampling rate may be decreased to 2 or 4 hourly if the ionised calcium is stable. Changing the clearance (filtrate rate) To increase clearance increases in the substitution flow (and filtrate flow) must be accompanied by a proportionate increase in blood flow, in order to keep the ratio between blood flow and citrate flow constant.( See table 1). Discuss this with the intensivist. If you change the prescription for the filtrate and blood flow (because you want a higher clearance, for example), then revert to hourly sampling until stable again. Other monitoring Electrolytes Magnesium (total) should be checked 12-24 hourly. Sodium should be checked every 6-12 hours. Author: David Buckley Page 5 of 8 Issued:

Calcium (total) should be checked 12-24 hourly, and in addition if more than two sequential increases in calcium chloride infusion rate have been needed, or if metabolic acidosis with rising anion gap occurs. See Acid/base below. Acid-Base Citrate is completely metabolised in most patients with normal liver function. A rising anion gap in a patient with a rising total calcium but a falling ionised calcium (despite increasing the calcium chloride infusion) is caused by citrate accumulation ( citrate lock ). This is more likely in patients who have poor liver function and those receiving large amounts of blood products(these can contain large amounts of citrate). Acidaemia is also likely to develop, with a falling bicarbonate, an increasing anion gap, and a decreasing base excess. (Under normal circumstances the citrate in the circuit blood will cause an anion gap which is 5-7 meq/l greater than the patient s anion gap. Therefore in assessing an anion gap it is important to do so on the patients blood not a circuit blood sample.) Citrate lock can only be managed by decreasing the citrate, i.e. substitution, fluid flow rate. REMEMBER this should not be less than 35ml/kg/min. If you need to continue at the same rate of filtrate removal then substitute the decreased citrate fluid with either NaCl or NaHCO 3 containing fluids depending upon the serum Na and bicarbonate concentrations. In some patients this situation continues to worsen and citrate anticoagulation may have to be abandoned and replaced by heparin anticoagulation and bicarbonate replacement fluid. Some patients with normal liver function may become alkalotic due to overproduction of bicarbonate from the citrate load. If this occurs use 0.45% or 0.9% saline as some of the replacement solution. Discuss with the intensivist. Stopping CVVH with citrate Cease the Calcium and Magnesium infusions immediately after ceasing citrate substitution fluid. Recheck plasma total and ionised calcium and total magnesium after 1 hour and 6 hours. Any of the findings below are an indication to alter treatment. Inform the PICU registrar or Consultant if any of the following. Ca ++ < 0.8 mmol/l or >1.5mmol/L Total serum Ca > 3 mmol/l Na + < 130mmol/L or Na + > 150mmol/L HCO 3 - > 35mmol/L ph < 7.3 or ph > 7.5 Base Excess < - 5 Patient Anion Gap > 8mmol/L Author: David Buckley Page 6 of 8 Issued:

NOTES 1. CHANGING CLEARANCE To increase clearance you need to increase the blood flow rate and maintain the ratio of substitution fluid rate to blood flow rate as per table 1. These are the starting values which are then adjusted as per tables 2 and 3. 2. CITRATE LOCK If citrate lock is developing as evidenced by acidosis, increased anion gap, and increasing ratio of total:ionised calcium then you need to decrease citrate delivery. It is important that the substitution fluid rate is kept at not less than 35ml/kg/hr. To achieve this and not give excess citrate then some of the substitution fluid will need to be given as either Hemosol (if patient acidotic), 0.9% saline (if patient alkalotic and serum sodium normal), or 0.45% saline (if patient alkalotic and serum sodium high). This fluid will have to be given and accounted for outside of the Aquarius fluid balance. A good starting dose is to replace 1/3 of the citrate substitution fluid with one of the above fluids. 3. RECORD KEEPING All patients need to have a data collection sheet completed for EACH filter that they use while on CVVH. Author: David Buckley Page 7 of 8 Issued:

Trial of Citrate Evaluation form Name: Use one of these forms for each circuit/filter Weight: Attach Patient Sticker Here Date this circuit started: Date this circuit ended: Anticoagulation Used: Reason for CVVH: Why did this circuit end (routine change, rising TMP or Rb, CVVH stopped, sudden clotting?) Date Time Blood flow rate Substit.flow rate CaCl 2 flow rate Why were the above changed? Ca i in circuit Ca i in patient Anion gap circuit Anion gap in pt. Mg in patient Original settings Record above information 12 hourly as close to 0600 and 1800 as practicable. Other comments: Author: David Buckley Page 8 of 8 Issued: